Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Aggrastat

Known as: Merck Frosst brand of tirofiban hydrochloride monohydrate, Agrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate 
 
National Institutes of Health

Related topics

Related topics

3 relations
15 ML tirofiban 0.25 MG/ML Injection [Aggrastat]

Broader (2)

TIROFIBAN HYDROCHLORIDEtirofiban

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Radiolabeled tirofiban – a potential radiopharmaceutical for detection of deep venous thrombosis
Aim The aim of this study was to investigate the possibility of using 99mtechnetium (99mTc)-labeled tirofiban (a reversible… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Effects of intracoronary tirofiban administration on diabetes mellitus complicated by acute myocardial infarction in female patients undergoing emergency percutaneous coronary intervention
This study aims to investigate the short-term efficacy and safety of intracoronary tirofiban administration during emergency… Expand
  • table 1
  • table 2
  • table 3
2015
2015
Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with ST-segment… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
2013
2013
Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous…
BACKGROUND We investigated whether an additional intracoronary tirofiban bolus administration following upstream intravenous… Expand
2011
2011
The Effect of Intracoronary Tirofiban Treatment on Acute Myocardial Infarction with ST Segment Elevation
Objective To observe the efficacy and the safety with intracoronary use of tirofiban therapy in acute myocardium infarction… Expand
2010
2010
Tirofiban 'bridging' therapy for patients with drug-eluting stents undergoing non-cardiac surgery.
Editor—We read with interest the report of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of… Expand
2005
2005
Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty
Glycoprotein IIb/IIIa inhibitor therapy during primary percutaneous coronary intervention (PCI) decreases the incidence of major… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2003
2003
Use of Abciximab and Tirofiban in Patients with Peripheral Arterial Occlusive Disease and Arterial Thrombosis
Acute peripheral arterial occlusive disease is an important factor affecting the mobility and mortality rate of elderly patients… Expand
  • table I
  • table II
  • table III
2003
2003
Effects of GP IIb/IIIa Receptor Inhibitor Tirofiban (Aggrastat) in Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis
The authors investigated the effects of the platelet glycoprotein IIb/IIIa platelet inhibitor, tirofiban, on stent thrombosis in… Expand
Review
2001
Review
2001
[GPIIb-IIIa inhibitors].
  • P. Nurden
  • Transfusion clinique et biologique : journal de…
  • 2001
    • Corpus ID: 31431866
Therapy involving the use of anti-GPIIb-IIIa inhibitors has progressively evolved in recent years for patients undergoing… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE